SG11202007664WA - Bispecific egfr/cd16 antigen-binding protein - Google Patents
Bispecific egfr/cd16 antigen-binding proteinInfo
- Publication number
- SG11202007664WA SG11202007664WA SG11202007664WA SG11202007664WA SG11202007664WA SG 11202007664W A SG11202007664W A SG 11202007664WA SG 11202007664W A SG11202007664W A SG 11202007664WA SG 11202007664W A SG11202007664W A SG 11202007664WA SG 11202007664W A SG11202007664W A SG 11202007664WA
- Authority
- SG
- Singapore
- Prior art keywords
- antigen
- binding protein
- bispecific egfr
- bispecific
- egfr
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001104—Epidermal growth factor receptors [EGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4203—Receptors for growth factors
- A61K40/4204—Epidermal growth factor receptors [EGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4224—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18161871 | 2018-03-14 | ||
| PCT/EP2019/056516 WO2019175368A1 (en) | 2018-03-14 | 2019-03-14 | Bispecific egfr/cd16 antigen-binding protein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202007664WA true SG11202007664WA (en) | 2020-09-29 |
Family
ID=61683598
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202007664WA SG11202007664WA (en) | 2018-03-14 | 2019-03-14 | Bispecific egfr/cd16 antigen-binding protein |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11510972B2 (https=) |
| EP (1) | EP3765157A1 (https=) |
| JP (1) | JP7288913B2 (https=) |
| KR (1) | KR102924742B1 (https=) |
| CN (1) | CN111971090B (https=) |
| AU (1) | AU2019235433B2 (https=) |
| BR (1) | BR112020018492A2 (https=) |
| CA (1) | CA3090464A1 (https=) |
| IL (1) | IL276903B2 (https=) |
| MX (1) | MX2020009445A (https=) |
| SG (1) | SG11202007664WA (https=) |
| WO (1) | WO2019175368A1 (https=) |
| ZA (1) | ZA202006247B (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL276903B2 (en) * | 2018-03-14 | 2025-12-01 | Affimed Gmbh | Bispecific egfr/cd16 antigen-binding protein |
| KR20220119467A (ko) | 2019-12-27 | 2022-08-29 | 아피메트 게엠베하 | 이중특이적 fcyriii x cd30 항체 작제물의 제조 방법 |
| WO2023006082A1 (zh) * | 2021-07-30 | 2023-02-02 | 启愈生物技术(上海)有限公司 | 抗原靶向、抗cd16a和免疫效应细胞激活三功能融合蛋白及其应用 |
| CN116143942A (zh) * | 2021-09-09 | 2023-05-23 | 启愈生物技术(上海)有限公司 | 抗原靶向、抗cd16a和免疫效应细胞激活三功能融合蛋白及其应用 |
| JP2024543828A (ja) * | 2021-11-03 | 2024-11-26 | アフィメド ゲーエムベーハー | 二重特異性ｃｄ１６ａバインダー |
| AU2022382368A1 (en) * | 2021-11-03 | 2024-05-02 | Affimed Gmbh | Bispecific cd16a binders |
| WO2024186092A1 (ko) * | 2023-03-06 | 2024-09-12 | 주식회사 드노보 바이오테라퓨틱스 | 신규한 항-cd16 항체 및 이의 용도 |
| WO2024213097A1 (zh) * | 2023-04-14 | 2024-10-17 | 山东先声生物制药有限公司 | 一种靶向人cd16和肿瘤抗原的多特异性抗体 |
| WO2025167357A1 (zh) * | 2024-02-06 | 2025-08-14 | 启愈生物技术(上海)有限公司 | Cd80/taa融合蛋白相关的肿瘤靶向、t细胞激活分子形式及其应用 |
| CN118221818B (zh) * | 2024-04-29 | 2025-01-24 | 四川大学 | 一种抗cd16a的纳米抗体及其应用 |
| WO2026017120A1 (zh) * | 2024-07-18 | 2026-01-22 | 信达生物制药(苏州)有限公司 | 抗cdh17/egfr/cd16a三特异性抗体及其用途 |
| CN118994409B (zh) * | 2024-07-30 | 2025-07-22 | 郑州市乘黄生物医药科技有限公司 | 结合CD16A和Trop2的双特异性抗体-NK细胞偶联物及其用途 |
| CN118791616A (zh) * | 2024-09-14 | 2024-10-18 | 苏州为度生物技术有限公司天津分公司 | 一种抗人cd16工程抗体及应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0510790D0 (en) | 2005-05-26 | 2005-06-29 | Syngenta Crop Protection Ag | Anti-CD16 binding molecules |
| US8289183B1 (en) | 2008-04-25 | 2012-10-16 | Texas Instruments Incorporated | System and method for solar panel array analysis |
| DK2560993T3 (da) | 2010-04-20 | 2024-10-14 | Genmab As | Heterodimeric antibody fc-containing proteins and methods for production thereof |
| CN105153307A (zh) * | 2010-05-04 | 2015-12-16 | 梅里麦克制药股份有限公司 | 抗表皮生长因子受体(egfr)的抗体及其用途 |
| LT2794658T (lt) * | 2011-12-19 | 2017-05-10 | Synimmune Gmbh | Bispecifinė antikūno molekulė |
| BR112015000167B1 (pt) | 2012-07-06 | 2021-11-23 | Genmab B.V. | Proteína dimérica, proteína, composição, kit de partes e seus usos, bem como método para aumentar a oligomerização em solução de uma proteína dimérica compreendendo um primeiro e segundo polipeptídeo, cada um compreendendo pelo menos as regiões ch2 e ch3 de uma cadeia pesada de igg1 humana e proteína dimérica variante |
| AU2014227638A1 (en) | 2013-03-15 | 2015-09-17 | Merck Patent Gmbh | Tetravalent bispecific antibodies |
| CN105555804B (zh) * | 2013-08-07 | 2020-12-25 | 阿菲姆德股份有限公司 | 对EGFRvIII有特异性的抗体结合位点 |
| TWI731535B (zh) * | 2014-03-21 | 2021-06-21 | 美商艾伯維有限公司 | 抗-egfr抗體及抗體藥物結合物 |
| EP2930188A1 (en) * | 2014-04-13 | 2015-10-14 | Affimed Therapeutics AG | Trifunctional antigen-binding molecule |
| ES2754557T3 (es) * | 2015-05-04 | 2020-04-20 | Affimed Gmbh | Combinación de un anticuerpo CD30XCD16A con un anticuerpo antagonista anti-PD-1 para terapia |
| EP3156417A1 (en) | 2015-10-13 | 2017-04-19 | Affimed GmbH | Multivalent fv antibodies |
| CN105367660B (zh) * | 2015-12-22 | 2018-12-21 | 深圳市北科生物科技有限公司 | 一种抗cd16a抗原和抗muc1抗原的双特异性抗体 |
| IL276903B2 (en) * | 2018-03-14 | 2025-12-01 | Affimed Gmbh | Bispecific egfr/cd16 antigen-binding protein |
-
2019
- 2019-03-14 IL IL276903A patent/IL276903B2/en unknown
- 2019-03-14 SG SG11202007664WA patent/SG11202007664WA/en unknown
- 2019-03-14 WO PCT/EP2019/056516 patent/WO2019175368A1/en not_active Ceased
- 2019-03-14 BR BR112020018492-6A patent/BR112020018492A2/pt unknown
- 2019-03-14 KR KR1020207029239A patent/KR102924742B1/ko active Active
- 2019-03-14 EP EP19715401.6A patent/EP3765157A1/en active Pending
- 2019-03-14 CN CN201980018525.9A patent/CN111971090B/zh active Active
- 2019-03-14 JP JP2020548991A patent/JP7288913B2/ja active Active
- 2019-03-14 MX MX2020009445A patent/MX2020009445A/es unknown
- 2019-03-14 AU AU2019235433A patent/AU2019235433B2/en active Active
- 2019-03-14 CA CA3090464A patent/CA3090464A1/en active Pending
-
2020
- 2020-09-02 US US17/010,622 patent/US11510972B2/en active Active
- 2020-10-08 ZA ZA2020/06247A patent/ZA202006247B/en unknown
-
2022
- 2022-10-19 US US18/047,917 patent/US12076384B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BR112020018492A2 (pt) | 2020-12-29 |
| JP7288913B2 (ja) | 2023-06-08 |
| KR20200132919A (ko) | 2020-11-25 |
| IL276903A (en) | 2020-10-29 |
| CN111971090A (zh) | 2020-11-20 |
| KR102924742B1 (ko) | 2026-02-10 |
| IL276903B2 (en) | 2025-12-01 |
| ZA202006247B (en) | 2021-09-29 |
| MX2020009445A (es) | 2020-10-08 |
| US20230190900A1 (en) | 2023-06-22 |
| CN111971090B (zh) | 2024-02-23 |
| AU2019235433A1 (en) | 2020-08-27 |
| WO2019175368A1 (en) | 2019-09-19 |
| US11510972B2 (en) | 2022-11-29 |
| CA3090464A1 (en) | 2019-09-19 |
| US12076384B2 (en) | 2024-09-03 |
| US20200405833A1 (en) | 2020-12-31 |
| RU2020131234A (ru) | 2022-03-22 |
| AU2019235433B2 (en) | 2025-11-20 |
| IL276903B1 (en) | 2025-08-01 |
| JP2021515798A (ja) | 2021-06-24 |
| EP3765157A1 (en) | 2021-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202006247B (en) | Bispecific egfr/cd16 antigen-binding protein | |
| IL279235A (en) | DLL3-CD3 bispecific antibodies | |
| IL283812A (en) | Humanized antibody against human pd–1 | |
| SG11202013138RA (en) | Anti-steap1 antigen-binding protein | |
| IL280882A (en) | Transgenic bispecific proteins | |
| IL283530A (en) | Bispecific anti-pd-l1/anti-4-1bb antibodies and their uses | |
| SG11202104441QA (en) | Humanized antibodies against c-kit | |
| ZA202004908B (en) | Bispecific antibody | |
| IL282756A (en) | Humanized antibodies against SIRPα | |
| EP3941944A4 (en) | Claudin-6 bispecific antibodies | |
| GB201710838D0 (en) | Bispecific antibodies | |
| IL277968A (en) | Anti-CD27 and anti-PD-L1 antibodies and bispecific constructs | |
| SG11202007735TA (en) | Anti-her2 antibodies | |
| GB201820554D0 (en) | BTLA antibodies | |
| IL286757A (en) | Antibodies in specific | |
| SG11202012148RA (en) | Monoclonal antibodies against human tim-3 | |
| IL282355A (en) | Bispecific antibodies directed to exosomes | |
| SG11202100607RA (en) | Humanized antibodies against psma | |
| IL286918A (en) | Bispecific antibody | |
| IL269577B (en) | Bispecific antibodies anti–pd–l1–anti–tim–3 | |
| ZA202206008B (en) | Bispecific anti-ccl2 antibodies | |
| IL290050A (en) | Bispecific antibody | |
| GB201820006D0 (en) | Humanised anti-IL17BR antibody | |
| GB201818618D0 (en) | Monoclonal antibodies against ambra-1 | |
| EP3901173A4 (en) | BISPECIFIC PROTEIN |